Who makes dexmedetomidine plus ketamine?

dexmedetomidine plus ketamine is developed by Benha University.

What development phase is dexmedetomidine plus ketamine in?

dexmedetomidine plus ketamine is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

dexmedetomidine plus ketamine

Benha University · FDA-approved active Small molecule Quality 1/100

Dexmedetomidine plus ketamine, developed by Benha University, is a marketed combination therapy. The key composition patent is set to expire in 2028, providing a clear period of exclusivity. The primary risk is the lack of detailed clinical trial results and revenue data, which may limit investor confidence and market adoption.

At a glance

Generic name	dexmedetomidine plus ketamine
Also known as	Group A
Sponsor	Benha University
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.